Ralph V. Boccia

Hematology Oncology | Oncology

6410 Rockledge Drive, Suite 660
Suite 660
Bethesda, MD 20817

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 19, 2025

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.

Journal: Targeted oncology

Published: March 04, 2024

Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.

Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.

Journal: Drugs - real world outcomes

Published: February 26, 2024

A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.

A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.

Journal: Journal of clinical medicine

Published: January 16, 2024

mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues.

mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues.

Journal: Nature biomedical engineering

Published: December 21, 2023

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.

Journal: Hematological oncology

Published: February 17, 2023

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.

Journal: Blood

Published: January 24, 2023

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.

Journal: British journal of haematology

Published: September 01, 2022

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: April 13, 2022

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis.

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis.

Journal: Journal of blood medicine

Published: November 19, 2021

Immune thrombocytopenia.

Immune thrombocytopenia.

Journal: Expert review of hematology

Published: November 01, 2021

Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).

Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).

Journal: American journal of hematology

Published: July 09, 2021

Showing 1-12 of 67

Last Updated: 09/26/2026